Det er derfor at lægemidler, som metaboliseres ved eller hæmmes af cytokrom P450, kan tillægges til et stabilt pravastatin regime uden at forårsage signifikante ændringer i plasmaværdierne for pravastatin, hvilket er set med andre statiner.
This is why products that are metabolised by, or inhibitors of, the cytochrome P450 system can be added to a stable regimen of pravastatin without causing significant changes in the plasma levels of pravastatin, as have been seen with other statins.